Regulus Therapeutics Inc RGLS

NAS: RGLS | ISIN: US75915K2006 23/05/2025

7,890 USD (-0,25%)

(-0,25%) 23/05/2025

Grafiek Regulus Therapeutics Inc

Grafiek Regulus Therapeutics Inc

1 dag1d -0,25%
1 week1w 0,25%
1 maand1m 185,87%
3 maanden3m 521,26%
6 maanden6m 419,08%
1 jaar1j 285,82%
5 jaar5j 1.081,14%

Regulus Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

8 mei 2025 · Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates · Persbericht

30 april 2025 · Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG · Persbericht

2 april 2025 · Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit · Persbericht

27 maart 2025 · Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

13 maart 2025 · Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates · Persbericht

4 maart 2025 · Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference · Persbericht

28 augustus 2024 · Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences · Persbericht

8 augustus 2024 · Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates · Persbericht

6 augustus 2024 · Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference · Persbericht

9 juli 2024 · Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences · Persbericht

Profiel Regulus Therapeutics Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.regulusrx.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: Joseph Hagan

Werknemers: 47

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe